Quote:

---

Nader sold shares to help meet supply deadlines and infuse cash into the company to get up-listed.

---

Not trying to be argumentative, but we were told in the last call that NASDAQ requires the equivalent of a total of 4 (four) previous quarter of operating expenses in order to qualify for uplisting.

As Dr. NP stated in that very same call, CytoDyn spent ~$55M in the past 4 quarters. He has also mentioned, on several occasions, that uplisting was not a priority.

So, I don't really think that he "sold shares to ... infuse cash into the company to get up-listed".

One could maybe say that indirectly, the infusion of cash helps us to achieve COVID approval, and (subsequently) attract funding/generate revenue, either of which might allow uplisting in the future. But I don't think his motivation relating to recent events had anything to do with uplisting.

Happy to hear other opinions and/or be proven wrong.